Niacin-bound chromium enhances myocardial protection from ischemia-reperfusion injury

Mahesh Thirunavukkarasu, Suresh Varma Penumathsa, B. Juhász, Lijun Zhan, Gerald Cordis, Elham Altaf, Manashi Bagchi, Debasis Bagchi, Nilanjana Maulik

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

A novel niacin-bound, chromium-based energy formula (EF; InterHealth Nutraceuticals, Benicia, CA) has been developed in conjunction with D-ribose, caffeine, ashwagandha extract (containing 5% withanolides), and selected amino acids. We have assessed the efficacy of oral administration of EF (40 mg·kg body wt-1·day-1) in male and female rats over a period of 90 consecutive days on the cardiovascular and pathophysiological functions in an isolated rat heart model. After 30, 60, and 90 days of treatment with EF, the hearts of male and female rats were subjected to 30 min of global ischemia followed by 2 h of reperfusion and were measured for myocardial ATP, creatine phosphate (CP), phosphorylated AMP kinase (p-AMPK), and heat shock proteins. Myocardial ATP and CP levels were increased in both male and female rats after EF treatment compared with the controls. Western blot analyses were performed to quantify the expression of stress-related proteins such as heat shock proteins (HSP-70, -32, and -25) and are found to be increased in both male and female rats after EF treatment. The p-AMPK level, which is a sensor for the energy state in various cell types, was also found to be increased after treatment with EF in both male and female rats. Aortic flow, maximum first derivative of developed pressure, left ventricular developed pressure, and infarct size were observed after ischemia-reperfusion and found to be significantly improved in EF-treated rats compared with control animals. Thus EF demonstrated long-term safety as well as exhibiting significant cardioprotective ability during ischemia and reperfusion injury by increased energy production, improved cardiac function, and reduced infarct size.

Original languageEnglish
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume291
Issue number2
DOIs
Publication statusPublished - 2006

Fingerprint

Niacin
Chromium
Reperfusion Injury
Myocardial Ischemia
Adenylate Kinase
Phosphocreatine
Heat-Shock Proteins
Reperfusion
Ischemia
Adenosine Triphosphate
HSP70 Heat-Shock Proteins
Ribose
Ventricular Pressure
Therapeutics
Dietary Supplements
Caffeine
Oral Administration
Western Blotting
Safety
Amino Acids

Keywords

  • Adenosine 5′-triphosphate
  • Heat shock proteins
  • Phosphorylated adenosine 5′-monophosphate kinase
  • Preconditioning

ASJC Scopus subject areas

  • Physiology

Cite this

Niacin-bound chromium enhances myocardial protection from ischemia-reperfusion injury. / Thirunavukkarasu, Mahesh; Penumathsa, Suresh Varma; Juhász, B.; Zhan, Lijun; Cordis, Gerald; Altaf, Elham; Bagchi, Manashi; Bagchi, Debasis; Maulik, Nilanjana.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 291, No. 2, 2006.

Research output: Contribution to journalArticle

Thirunavukkarasu, Mahesh ; Penumathsa, Suresh Varma ; Juhász, B. ; Zhan, Lijun ; Cordis, Gerald ; Altaf, Elham ; Bagchi, Manashi ; Bagchi, Debasis ; Maulik, Nilanjana. / Niacin-bound chromium enhances myocardial protection from ischemia-reperfusion injury. In: American Journal of Physiology - Heart and Circulatory Physiology. 2006 ; Vol. 291, No. 2.
@article{0d2a902b14a149c8afbcefd28c93b9aa,
title = "Niacin-bound chromium enhances myocardial protection from ischemia-reperfusion injury",
abstract = "A novel niacin-bound, chromium-based energy formula (EF; InterHealth Nutraceuticals, Benicia, CA) has been developed in conjunction with D-ribose, caffeine, ashwagandha extract (containing 5{\%} withanolides), and selected amino acids. We have assessed the efficacy of oral administration of EF (40 mg·kg body wt-1·day-1) in male and female rats over a period of 90 consecutive days on the cardiovascular and pathophysiological functions in an isolated rat heart model. After 30, 60, and 90 days of treatment with EF, the hearts of male and female rats were subjected to 30 min of global ischemia followed by 2 h of reperfusion and were measured for myocardial ATP, creatine phosphate (CP), phosphorylated AMP kinase (p-AMPK), and heat shock proteins. Myocardial ATP and CP levels were increased in both male and female rats after EF treatment compared with the controls. Western blot analyses were performed to quantify the expression of stress-related proteins such as heat shock proteins (HSP-70, -32, and -25) and are found to be increased in both male and female rats after EF treatment. The p-AMPK level, which is a sensor for the energy state in various cell types, was also found to be increased after treatment with EF in both male and female rats. Aortic flow, maximum first derivative of developed pressure, left ventricular developed pressure, and infarct size were observed after ischemia-reperfusion and found to be significantly improved in EF-treated rats compared with control animals. Thus EF demonstrated long-term safety as well as exhibiting significant cardioprotective ability during ischemia and reperfusion injury by increased energy production, improved cardiac function, and reduced infarct size.",
keywords = "Adenosine 5′-triphosphate, Heat shock proteins, Phosphorylated adenosine 5′-monophosphate kinase, Preconditioning",
author = "Mahesh Thirunavukkarasu and Penumathsa, {Suresh Varma} and B. Juh{\'a}sz and Lijun Zhan and Gerald Cordis and Elham Altaf and Manashi Bagchi and Debasis Bagchi and Nilanjana Maulik",
year = "2006",
doi = "10.1152/ajpheart.00134.2006",
language = "English",
volume = "291",
journal = "American Journal of Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "2",

}

TY - JOUR

T1 - Niacin-bound chromium enhances myocardial protection from ischemia-reperfusion injury

AU - Thirunavukkarasu, Mahesh

AU - Penumathsa, Suresh Varma

AU - Juhász, B.

AU - Zhan, Lijun

AU - Cordis, Gerald

AU - Altaf, Elham

AU - Bagchi, Manashi

AU - Bagchi, Debasis

AU - Maulik, Nilanjana

PY - 2006

Y1 - 2006

N2 - A novel niacin-bound, chromium-based energy formula (EF; InterHealth Nutraceuticals, Benicia, CA) has been developed in conjunction with D-ribose, caffeine, ashwagandha extract (containing 5% withanolides), and selected amino acids. We have assessed the efficacy of oral administration of EF (40 mg·kg body wt-1·day-1) in male and female rats over a period of 90 consecutive days on the cardiovascular and pathophysiological functions in an isolated rat heart model. After 30, 60, and 90 days of treatment with EF, the hearts of male and female rats were subjected to 30 min of global ischemia followed by 2 h of reperfusion and were measured for myocardial ATP, creatine phosphate (CP), phosphorylated AMP kinase (p-AMPK), and heat shock proteins. Myocardial ATP and CP levels were increased in both male and female rats after EF treatment compared with the controls. Western blot analyses were performed to quantify the expression of stress-related proteins such as heat shock proteins (HSP-70, -32, and -25) and are found to be increased in both male and female rats after EF treatment. The p-AMPK level, which is a sensor for the energy state in various cell types, was also found to be increased after treatment with EF in both male and female rats. Aortic flow, maximum first derivative of developed pressure, left ventricular developed pressure, and infarct size were observed after ischemia-reperfusion and found to be significantly improved in EF-treated rats compared with control animals. Thus EF demonstrated long-term safety as well as exhibiting significant cardioprotective ability during ischemia and reperfusion injury by increased energy production, improved cardiac function, and reduced infarct size.

AB - A novel niacin-bound, chromium-based energy formula (EF; InterHealth Nutraceuticals, Benicia, CA) has been developed in conjunction with D-ribose, caffeine, ashwagandha extract (containing 5% withanolides), and selected amino acids. We have assessed the efficacy of oral administration of EF (40 mg·kg body wt-1·day-1) in male and female rats over a period of 90 consecutive days on the cardiovascular and pathophysiological functions in an isolated rat heart model. After 30, 60, and 90 days of treatment with EF, the hearts of male and female rats were subjected to 30 min of global ischemia followed by 2 h of reperfusion and were measured for myocardial ATP, creatine phosphate (CP), phosphorylated AMP kinase (p-AMPK), and heat shock proteins. Myocardial ATP and CP levels were increased in both male and female rats after EF treatment compared with the controls. Western blot analyses were performed to quantify the expression of stress-related proteins such as heat shock proteins (HSP-70, -32, and -25) and are found to be increased in both male and female rats after EF treatment. The p-AMPK level, which is a sensor for the energy state in various cell types, was also found to be increased after treatment with EF in both male and female rats. Aortic flow, maximum first derivative of developed pressure, left ventricular developed pressure, and infarct size were observed after ischemia-reperfusion and found to be significantly improved in EF-treated rats compared with control animals. Thus EF demonstrated long-term safety as well as exhibiting significant cardioprotective ability during ischemia and reperfusion injury by increased energy production, improved cardiac function, and reduced infarct size.

KW - Adenosine 5′-triphosphate

KW - Heat shock proteins

KW - Phosphorylated adenosine 5′-monophosphate kinase

KW - Preconditioning

UR - http://www.scopus.com/inward/record.url?scp=33746807642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746807642&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00134.2006

DO - 10.1152/ajpheart.00134.2006

M3 - Article

C2 - 16840737

AN - SCOPUS:33746807642

VL - 291

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6119

IS - 2

ER -